advanced search
THE CRITICALITY OF ADHESIVE SELECTION FOR OPTIMAL TRANSDERMAL DRUG DELIVERY SYSTEMS
TRANSDERMAL
Megan Greth
THE CRITICALITY OF ADHESIVE SELECTION FOR OPTIMAL TRANSDERMAL DRUG DELIVERY SYSTEMS
Megan Greth and Gozde Karabiyik discuss why selecting the right adhesive for body-worn drug delivery systems – be they transdermal patches or wearable injection devices or pumps – is critical for a successful outcome.
OPTIMISING <i>IN VITRO</i> TESTING FOR TRANSDERMAL AND TOPICAL DRUG PRODUCTS
TRANSDERMAL
Tony Copley
Copley Scientific
OPTIMISING IN VITRO TESTING FOR TRANSDERMAL AND TOPICAL DRUG PRODUCTS
Tony Copley examines the regulatory framework for transdermal and topical products and popular, effective and cost-efficient in vitro testing techniques for quantifying their release characteristics.
NEW RESEARCH TOOLS FOR TOPICAL & TRANSDERMAL DEVELOPMENT
TRANSDERMAL
Prof Marc Brown
MedPharm
NEW RESEARCH TOOLS FOR TOPICAL & TRANSDERMAL DEVELOPMENT
Marc Brown, Rob Turner and James Gibbons provide a view on the current topical and transdermal market, elaborate on some of the common approaches to product development in this area, and reveal the company’s newest model, the MedFlux-HT™ system.
MICROBRISTLE APPLICATOR (MBA™) SYSTEMS FOR TOPICAL AND TRANSDERMAL DRUG APPLICATION
TRANSDERMAL
Pierre Michelet
MICROBRISTLE APPLICATOR (MBA™) SYSTEMS FOR TOPICAL AND TRANSDERMAL DRUG APPLICATION
Pierre Michelet, Karl Hartstock-Martin, and Moritz Beyhl present the innovative technology of microbristle applicators (MBA™) for a more precise and hygienic application within topical and transdermal treatment. MBA™ comprises a platform of moulded, pure plastic applicators with very fine bristles to apply liquid and semi-liquid formulations.
INSIGHTS FROM THE YPSOMATE SMART CASE STUDY
PREFILLED SYRINGES
Dr Andreas Schneider
Ypsomed
INSIGHTS FROM THE YPSOMATE SMART CASE STUDY
Andreas Schneider provides insights into recent development activities at Ypsomed in the area of smart self-injection systems.
THE POWER OF DRUG-DEVICE COMPANY COLLABORATION
PREFILLED SYRINGES
Bill Welch
Phillips-Medisize
THE POWER OF DRUG-DEVICE COMPANY COLLABORATION
During the Pharmapack Europe Conference (Paris, France) – at 4pm on Wednesday, February 10th, 2016 – Bill Welch, Chief Technology Officer, Phillips-Medisize Corporation, will give a lecture entitled “Integrated Development and Scale-Up of Combination Products”. Here, he provides us with a preview of his forthcoming Pharmapack talk.
AN INNOVATIVE SOLUTION TO ADDRESS SILICONE-RELATED CONCERNS
PREFILLED SYRINGES
Christian Herget
BD (Becton Dickinson & Company)
AN INNOVATIVE SOLUTION TO ADDRESS SILICONE-RELATED CONCERNS
Christian Herget explores the potential impacts of silicone coatings on prefilled syringe-based injectable biopharmaceutical combination products and recent advances at BD to reduce these impacts.
HIGH-END PREFILLABLE SYRINGES FOR INNOVATIVE BIOPHARMACEUTICALS
PREFILLED SYRINGES
Klaus Wanner
HIGH-END PREFILLABLE SYRINGES FOR INNOVATIVE BIOPHARMACEUTICALS
HEKUMA provides detailed insights into how specific process challenges arose and describes a resulting manufacturing line that excels in precision, technical reliability and cleanliness of the manufacturing environment to produce a syringe featuring highest product performance attributes.
INTRODUCING A NOVEL CLASS OF ENGINEERED POLYMER
PREFILLED SYRINGES
Satoru Adachi
INTRODUCING A NOVEL CLASS OF ENGINEERED POLYMER
Satoru Adachi and Mark Nevitt highlight some of the concerns of using conventional glass for parenteral drug storage in prefilled syringes, and provide an update on ZEONEX® cycloolefin polymer (COP).
ASSESSING THE IMPACT ON DRUG DOSE DELIVERY OF PASSIVE SAFETY DEVICES
PREFILLED SYRINGES
Adrien Tisserand
Nemera
ASSESSING THE IMPACT ON DRUG DOSE DELIVERY OF PASSIVE SAFETY DEVICES
Adrien Tisserand reports findings from a comparative study on drug dose delivery of the company’s passive needle-safety platform, Safe’n’Sound®.
QUALITY & SYSTEMS USABILITY REQUIREMENTS
PREFILLED SYRINGES
Dr Michael Gross
QUALITY & SYSTEMS USABILITY REQUIREMENTS
Michael Gross and Adam Shames discuss US FDA quality system requirements for combination products, especially Design Controls, which includes the requirement to validate the design of the medical device constituent part of a combination/borderline product.
POLYMERS, GLASS AND PARTICULATES: CHOOSING THE BEST CONTAINMENT FOR CUTTING-EDGE BIOLOGICS
PREFILLED SYRINGES
Kevin Cancelliere
West Pharmaceutical Services
POLYMERS, GLASS AND PARTICULATES: CHOOSING THE BEST CONTAINMENT FOR CUTTING-EDGE BIOLOGICS
Kevin Cancelliere provides a run-down of the benefits that cyclic-olefin polymers syringes can bring compared with glass.
REDUCING PARTICULATES FROM METAL PRODUCTS IN MEDICAL DEVICES
PREFILLED SYRINGES
Graham Perkins
REDUCING PARTICULATES FROM METAL PRODUCTS IN MEDICAL DEVICES
Graham Perkins explains how, for medical device component manufactures, developing new methods to reduce particulates is becoming increasingly important.
INNOVATIVE ADVANCED DRUG DELIVERY PRODUCTS AND SERVICES THAT SATISFY FUNDAMENTAL NEEDS
PREFILLED SYRINGES
SHL Medical
INNOVATIVE ADVANCED DRUG DELIVERY PRODUCTS AND SERVICES THAT SATISFY FUNDAMENTAL NEEDS
SHL Group first explores the importance of fundamental design principles in injector design, as exemplified by the Molly® auto injector.
NOVEL APPROACHES & TECHNOLOGIES TO INCREASE PATIENT CONFIDENCE & DECREASE ANXIETY
PREFILLED SYRINGES
Joe Reynolds
Noble
NOVEL APPROACHES & TECHNOLOGIES TO INCREASE PATIENT CONFIDENCE & DECREASE ANXIETY
Joe Reynolds outlines some of the fundamental principles and benefits of training devices in the context of prefilled syringes, and highlights some specific training device technologies including novel needle simulators and angle aids.
A TOPICAL OCULAR RING DESIGNED TO REPLACE GLAUCOMA EYE DROPS
OCULAR
Anne Brody Rubin
A TOPICAL OCULAR RING DESIGNED TO REPLACE GLAUCOMA EYE DROPS
Anne Brody Rubin introduces ForSight VISION5's ring-shaped ocular insert containing prostaglandin for the lowering of intra-ocular pressure in glaucoma.
OPSISPORIN: A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS
OCULAR
Dr Paul Seaman
OPSISPORIN: A LONG-ACTING DRUG DELIVERY APPROACH FOR UVEITIS
Here, Paul Seaman and Daniel Palmer discuss Midatech Pharma’s next generation treatments for auto-immune ocular diseases, which use a combination of innovative, sustained-release drug products.
NEW SOLUTIONS FOR OPHTHALMIC DRUG DELIVERY USING BIODEGRADABLE SILICA MATRIX
OCULAR
Dr Mika Jokinen
NEW SOLUTIONS FOR OPHTHALMIC DRUG DELIVERY USING BIODEGRADABLE SILICA MATRIX
Mika Jokinen, Cora Griffin, and Lasse Leino, PhD describe the novel opportunities that biodegradable silica matrix technology offers to ophthalmic drug delivery.
IMPROVING OPHTHALMIC DRUG DELIVERY WITH NOVEL EMULSION TECHNOLOGIES
OCULAR
Robin de Bruijn
IMPROVING OPHTHALMIC DRUG DELIVERY WITH NOVEL EMULSION TECHNOLOGIES
Robin de Bruijn and Frank de Jong describe EmulTech’s ET4ME micro-encapsulation process, and its suitability as a particle formation technology for enhancing and enabling ophthalmic injectables.
USING INTELLIGENT DESIGN TO DELIVER SAFE MULTI-DOSE EYE DROPS
OCULAR
Fanny Sellier
Nemera
USING INTELLIGENT DESIGN TO DELIVER SAFE MULTI-DOSE EYE DROPS
Ms Fanny Sellier, explains how the intelligent design of multi-dose bottles provides a viable means of delivering safe, preservative-free eye drops.
SUSTAINED-RELEASE OCULAR DELIVERY TECHNOLOGIES
EXPERT VIEW
Michael O'Rourke
SUSTAINED-RELEASE OCULAR DELIVERY TECHNOLOGIES
Michael O'Rourke discusses the advances in the development and launching of sustained-release ocular drug delivery systems seen in recent years.
SCALEABILITY OF MICRO INTRAOCULAR IMPLANTS AND DEVICES
OCULAR
Donna Bibber
SCALEABILITY OF MICRO INTRAOCULAR IMPLANTS AND DEVICES
Donna Bibber discusses some of these micro-intraocular implants and devices and the scalability challenges associated with each, from the perspective of a plastics engineer.
THERAPY WITHOUT DROPS: A REALITY
OCULAR
Chris Muller
THERAPY WITHOUT DROPS: A REALITY
Chris Muller and Deepank Utkhede introduce Mati Therapeutics' Evolute® ocular delivery system, a non-invasive, sustained-release platform that combines a novel punctal plug with a sustained release drug eluting core.
INTRODUCING OCUSURF™ NANOSTRUCTURED EMULSION AS A 505(B)(2) STRATEGY
OCULAR
Dr Shikha P Barman
INTRODUCING OCUSURF™ NANOSTRUCTURED EMULSION AS A 505(B)(2) STRATEGY
Shikha P Barman describes how Integral Biosystems is developing a series of ophthalmic products with its OcuSurf platform.

See what ondrugdelivery's readers and contributors think


Abby Lockwood Opus Strategy photo
Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.


Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.


Matt Kempton user photo
Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.


Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.


Top